Table 3.
Baseline conditions of patients in clinical efficacy analysis.
| Ineffective (n = 7) | Effective (n = 17) | |
|---|---|---|
| Underlying diseases | ||
| Burn injury | 0 (0%) | 1 (5.9%) |
| Cardiovascular disease | 0 (0%) | 3 (17.6%) |
| Cerebrovascular disease | 0 (0%) | 1 (5.9%) |
| Crohn’s disease | 1 (14.3%) | 0 (0%) |
| Interstitial pneumonia | 0 (0%) | 2 (11.8%) |
| Kidney transplantation | 2 (28.6%) | 1 (5.9%) |
| Liver transplantation | 1 (14.3%) | 1 (5.9%) |
| Septic arthritis | 1 (14.3%) | 0 (0%) |
| Solid tumor | 2 (28.6%) | 8 (47.1%) |
| Type of infection | ||
| Bacteremia | 1 (14.3%) | 2 (11.8%) |
| CRBSI | 0 (0%) | 1 (5.9%) |
| Cholangitis | 1 (14.3%) | 3 (17.6%) |
| Cholecystitis | 0 (0%) | 2 (11.8%) |
| Infectious endocarditis | 0 (0%) | 1 (5.9%) |
| Liver abscess | 0 (0%) | 1 (5.9%) |
| Peritonitis | 1 (14.3%) | 0 (0%) |
| Pneumonia | 1 (14.3%) | 6 (35.3%) |
| Skin and soft tissue infection | 1 (14.3%) | 1 (5.9%) |
| Urinary tract infection | 3 (42.9%) | 2 (11.8%) |
| Isolated Gram-positive organisms | ||
| Enterococcus casseliflavus | 1 (14.3%) | 1 (5.9%) |
| Enterococcus faecalis | 0 (0%) | 2 (11.8%) |
| Enterococcus faecium | 1 (14.3%) | 5 (29.4%) |
| Parvimonas micra | 1 (14.3%) | 0 (0%) |
| MRSA | 3 (42.9%) | 10 (58.8%) |
| Staphylococcus epidermidis | 2 (28.6%) | 1 (5.9%) |
No patients had other bacterial infections, received steroids or antibiotics other than TEIC, underwent mechanical ventilation, or had a surgical history within one week prior to TEIC treatment. CRBSI, catheter-related bloodstream infection; MRSA, methicillin-resistant Staphylococcus aureus.